Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats

G Youcef; A Olivier; N Nicot; A Muller; C Deng; C Labat; R Fay; R-M Rodriguez-Guéant; C Leroy; F Jaisser; F Zannad; P Lacolley; L Vallar; A Pizard

doi:10.1111/bph.13479

Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats

British Journal of Pharmacology ◽

10.1111/bph.13479 ◽

2016 ◽

Vol 173 (11) ◽

pp. 1805-1819 ◽

Cited By ~ 12

Author(s):

G Youcef ◽

A Olivier ◽

N Nicot ◽

A Muller ◽

C Deng ◽

...

Keyword(s):

Mineralocorticoid Receptor ◽

Receptor Antagonism ◽

Mineralocorticoid Receptor Antagonism

Download Full-text

Faculty Opinions recommendation of Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725835891.793510469 ◽

2015 ◽

Author(s):

Luis Ruilope ◽

Enrique Morales

Keyword(s):

Chronic Kidney Disease ◽

Cardiovascular Risk ◽

Kidney Disease ◽

Mineralocorticoid Receptor ◽

Receptor Antagonism ◽

Mineralocorticoid Receptor Antagonism

Download Full-text

Faculty Opinions recommendation of Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725989934.793514779 ◽

2016 ◽

Author(s):

Luis Ruilope ◽

Enrique Morales

Keyword(s):

Renal Disease ◽

Mineralocorticoid Receptor ◽

Receptor Antagonism ◽

Mineralocorticoid Receptor Antagonism

Download Full-text

Mineralocorticoid Receptor Antagonism Ameliorates Left Ventricular Diastolic Dysfunction and Myocardial Fibrosis in Mildly Symptomatic Patients With Idiopathic Dilated Cardiomyopathy

Circulation ◽

10.1161/circulationaha.105.571653 ◽

2005 ◽

Vol 112 (19) ◽

pp. 2940-2945 ◽

Cited By ~ 163

Author(s):

Hideo Izawa ◽

Toyoaki Murohara ◽

Kohzo Nagata ◽

Satoshi Isobe ◽

Hiroyuki Asano ◽

...

Keyword(s):

Dilated Cardiomyopathy ◽

Diastolic Dysfunction ◽

Myocardial Fibrosis ◽

Mineralocorticoid Receptor ◽

Left Ventricular Diastolic Dysfunction ◽

Left Ventricular ◽

Idiopathic Dilated Cardiomyopathy ◽

Receptor Antagonism ◽

Ventricular Diastolic Dysfunction ◽

Mineralocorticoid Receptor Antagonism

Download Full-text

Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans

Journal of the American Society of Hypertension ◽

10.1016/j.jash.2014.04.011 ◽

2014 ◽

Vol 8 (7) ◽

pp. 475-480 ◽

Cited By ~ 25

Author(s):

Cheryl L. Laffer ◽

Fernando Elijovich ◽

George J. Eckert ◽

Wanzhu Tu ◽

J. Howard Pratt ◽

...

Keyword(s):

Blood Pressure ◽

Genetic Variation ◽

Pilot Study ◽

African Americans ◽

Mineralocorticoid Receptor ◽

Blood Pressure Response ◽

Pressure Response ◽

Receptor Antagonism ◽

Mineralocorticoid Receptor Antagonism

Download Full-text

Mineralocorticoid Receptor Antagonism Treatment for All Patients With ST-Segment Myocardial Infarction?

JAMA Internal Medicine ◽

10.1001/jamainternmed.2018.5950 ◽

2018 ◽

Vol 178 (11) ◽

pp. 1567

Author(s):

Robin A. P. Weir

Keyword(s):

Myocardial Infarction ◽

Mineralocorticoid Receptor ◽

Receptor Antagonism ◽

St Segment ◽

Mineralocorticoid Receptor Antagonism

Download Full-text

Mineralocorticoid receptor antagonism reverses diabetes-related coronary vasodilator dysfunction: A unique vascular transcriptomic signature

Pharmacological Research ◽

10.1016/j.phrs.2018.06.002 ◽

2018 ◽

Vol 134 ◽

pp. 100-108 ◽

Cited By ~ 2

Author(s):

Scott M. Brown ◽

Alex I. Meuth ◽

J. Wade Davis ◽

R. Scott Rector ◽

Shawn B. Bender

Keyword(s):

Mineralocorticoid Receptor ◽

Receptor Antagonism ◽

Coronary Vasodilator ◽

Mineralocorticoid Receptor Antagonism ◽

Transcriptomic Signature

Download Full-text

Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females

Biology of Sex Differences ◽

10.1186/s13293-019-0238-6 ◽

2019 ◽

Vol 10 (1) ◽

Cited By ~ 1

Author(s):

John S. Clemmer ◽

Jessica L. Faulkner ◽

Alex J. Mullen ◽

Kenneth R. Butler ◽

Robert L. Hester

Keyword(s):

African American ◽

African American Males ◽

Mineralocorticoid Receptor ◽

Receptor Antagonism ◽

Mineralocorticoid Receptor Antagonism ◽

Males And Females

Download Full-text

0278 : Mineralocorticoid receptor antagonism with BR-4628 protects against renal injury induced by ischemia/reperfusion

Archives of Cardiovascular Diseases Supplements ◽

10.1016/s1878-6480(15)30058-6 ◽

2015 ◽

Vol 7 (2) ◽

pp. 152 ◽

Cited By ~ 1

Author(s):

Alan Le Mercier ◽

Jonatan Barrera-Chimal ◽

Sonia Prince ◽

Fouad Fadel ◽

Soumaya El Moghrabi ◽

...

Keyword(s):

Renal Injury ◽

Mineralocorticoid Receptor ◽

Ischemia Reperfusion ◽

Receptor Antagonism ◽

Mineralocorticoid Receptor Antagonism

Download Full-text

Is there a new dawn for selective mineralocorticoid receptor antagonism?

Current Opinion in Nephrology & Hypertension ◽

10.1097/mnh.0000000000000051 ◽

2014 ◽

Vol 23 (5) ◽

pp. 456-461 ◽

Cited By ~ 6

Author(s):

James M. Luther

Keyword(s):

Mineralocorticoid Receptor ◽

Receptor Antagonism ◽

Mineralocorticoid Receptor Antagonism

Download Full-text

Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues

Journal of Clinical Hypertension ◽

10.1111/jch.12718 ◽

2015 ◽

Vol 18 (3) ◽

pp. 197-199 ◽

Cited By ~ 2

Author(s):

Panagiotis I. Georgianos ◽

Pantelis A. Sarafidis ◽

Vassilios Liakopoulos ◽

Elias V. Balaskas ◽

Pantelis E. Zebekakis

Keyword(s):

Renal Disease ◽

End Stage Renal Disease ◽

Mineralocorticoid Receptor ◽

Receptor Antagonism ◽

Cardiovascular Protection ◽

Mineralocorticoid Receptor Antagonism ◽

Stage Renal Disease ◽

End Stage

Download Full-text